Tazemetostat Hydrobromide Tablet shortage
Tazemetostat Hydrobromide Tablet is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 24, 2026.
Epizyme is permanently stopping production of Tazemetostat Hydrobromide tablets (the cancer medicine sold as Tazverik), and no supply remains. No other manufacturer of this medicine has been found in our records.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Tazemetostat Hydrobromide Tablet. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Mar 27, 2026Currently in shortage1 of 1 product affected.
-
Mar 27, 2026First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Epizyme, Inc. (An Ipsen Company) 📞 (855)-463-5127 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Tazverik, Tablet, 200 mg (NDC 72607-100-00) | — | — | Discontinuation of the manufacture of the drug product | — |
These rows are manufacturer reports to the FDA for Tazemetostat Hydrobromide Tablet — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Tazemetostat Hydrobromide Tablet? options further down this page.
Why is Tazemetostat Hydrobromide Tablet in shortage?
Epizyme, Inc. (an Ipsen company) has reported to the FDA that they are permanently stopping the manufacturing of Tazverik (tazemetostat) 200 mg tablets. This means this specific product — the 200 mg tablet form — will no longer be made by this manufacturer going forward.
It's worth knowing that Epizyme did not share a specific public reason why they made this decision, just that the discontinuation of manufacturing has been reported to the FDA. This report reflects only what Epizyme has filed, so it speaks only to their product and doesn't necessarily tell us the full picture across the entire marketplace.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Tazemetostat Hydrobromide Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Tazemetostat Hydrobromide Tablet?
Tazemetostat (brand name Tazverik) is currently listed on the FDA drug-shortage list. I want to walk you through what this means so you know your next step.
This medicine comes in one strength, 200 mg, and that strength has no available source reported right now. The manufacturer, Epizyme (an Ipsen Company), has reported that it is discontinuing the manufacture of this product. Because the record shows the product is being discontinued rather than temporarily short, this supply problem may be permanent. No other maker of this exact medicine appears in our records at this time.
Please keep taking your medicine as prescribed while this is sorted out. Do not stop or change your dose on your own.
Here is what I suggest:
- Contact your prescriber or pharmacist soon to discuss your options, since this medicine is being discontinued and a plan for what comes next is the right step.
- Ask your pharmacy to check whether any stock remains at wholesalers, though supply may be limited.
- For reference, the manufacturer's contact number is listed on this page; pharmacies usually handle those calls.
This information comes from national, manufacturer-reported FDA data and may not match what your local pharmacy has on hand. It is general information, not personal medical advice.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Therapeutic equivalents & pricing 1 productclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Tazverik 200 mg | Epizyme, | 240 tablets | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Identity & classification
Where does this data come from?
Other oncology shortages
Tazemetostat Hydrobromide Tablet shortage FAQs
Is Tazemetostat Hydrobromide Tablet in shortage?
Which products are affected?
When will Tazemetostat Hydrobromide Tablet be available again?
What should I do if I take Tazemetostat Hydrobromide Tablet?
Still have a question about the Tazemetostat Hydrobromide Tablet shortage?
Ask a pharmacist about this shortage →View Tazemetostat Hydrobromide Tablet on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.